<DOC>
	<DOC>NCT00651846</DOC>
	<brief_summary>The objective of this study was to investigate the impact of the oral contraceptive YASMIN (containing: drospirenone 3 mg/ethinyl estradiol 30 mcg) in comparison with the oral contraceptive MICROGYNON (containing: levonorgestrel 150 mcg/ethinyl estradiol 30mcg) on factors of blood coagulation and fibrinolysis in female subjects</brief_summary>
	<brief_title>Investigate Impact of Yasmin vs Microgynon on Hemostasis Parameters in Healthy Women</brief_title>
	<detailed_description />
	<mesh_term>Hemostatics</mesh_term>
	<mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
	<mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
	<mesh_term>Drospirenone and ethinyl estradiol combination</mesh_term>
	<criteria>Clinically normal safety laboratory results Standard contraindications for use of combined oral contraceptives (class label). Including: Presence or history of thromboembolic process in veins (such as deep venous thrombosis, pulmonary embolism) or arteries (e.g., stroke, myocardial infarction) or a known genetic component (homozygous), venous thromboembolic event in a close relative (parents or siblings) at younger age (&lt;/= 40 years) Acute and chronic severe liver dysfunction or disease. There should be an interval of at least 6 months between the subsidence of a viral hepatitis (normalization of the liver parameters) and the start of the study medication. Use of preparations where experience shows affect on the activity of hepatic enzymes.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Contraception</keyword>
	<keyword>Hemostasis</keyword>
	<keyword>Blood Coagulation</keyword>
</DOC>